Analyst Price Target is $4.50
▲ +89.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $4.50, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 89.87% upside from the last price of $2.37.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Geron. This Buy consensus rating has held steady for over two years.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.